We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > axSpA

News List

AbbVie submits applications for Upadacitinib in to US FDA and EMA ExpressPharma
January 10, 2022
In the trial study, evaluating the efficacy and safety of Upadacitinib in adult patients with nr-axSpA, Upadacitinib met its primary and most-ranked secondary endpoints.
NICE backs Lilly’s Taltz for axial spondyloarthritis pharmatimes
June 18, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly’s Taltz for the treatment of active ankylosing spondylitis (axSpA).
UCB’s Cimzia bags EU label extension pharmatimes
August 07, 2020
The European Medicines Agency (EMA) has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adult patients with axial spondyloarthritis (axSpA) at a reduced maintenance dose.